Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
93 hedge funds and large institutions have $187M invested in Epizyme, Inc in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 15 increasing their positions, 30 reducing their positions, and 54 closing their positions.
969% more call options, than puts
Call options by funds: $3.85M | Put options by funds: $360K
5% more capital invested
Capital invested by funds: $177M → $187M (+$9.55M)
23% less funds holding
Funds holding: 120 → 93 (-27)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
46% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 54
50% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$5.56M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.62M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$2.12M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$1.74M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.22M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.71M |
| 3 |
Millennium Management
New York
|
-$3.43M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.37M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.88M |
EPZM Hedge Fund Activity: Q2 2022 in Review
93 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2022, worth a combined $187M — up 5.4% from $177M a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of EPZM and 29 opened new positions — a net loss of 25 holders — while 30 trimmed existing stakes and 15 added.
The largest buyer was Newtyn Management, opening a new position worth an estimated $5.56M. The largest seller was BlackRock, cutting an estimated $5.22M.
- 93 institutional investors held Epizyme, Inc (EPZM) as of Q2 2022, down from 120 in Q1 2022.
- Funds reported $187M of Epizyme, Inc stock for Q2 2022, up 5.4% quarter-over-quarter.
- 29 funds opened new Epizyme, Inc positions in Q2 2022 and 54 closed out, a net change of -25 holders.
- The largest Epizyme, Inc buyer in Q2 2022 was Newtyn Management, an estimated $5.56M added.
- The largest Epizyme, Inc seller in Q2 2022 was BlackRock, an estimated $5.22M sold.
Based on aggregated 13F filings for Q2 2022.